Standigm

About:

Standigm is an AI-driven workflow drug discovery company that aims to improve the success rates and efficiency of new drug development.

Website: http://www.standigm.com

Top Investors: SK geo centric, TIPS Program, DSC Investment, Mirae Asset Venture Investment, LB Investment

Description:

Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing.

Total Funding Amount:

$71.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seoul, Seoul-t'ukpyolsi, South Korea

Founded Date:

2015-05-04

Contact Email:

business(AT)standigm.com

Founders:

Jinhan Kim, Sang Ok Song, So Jeong Yun

Number of Employees:

101-250

Last Funding Date:

2021-06-30

IPO Status:

Private

© 2024 MyAiNote.com